A review on newly approved PARP inhibitors: Talazoparib and Olaparib

This project report is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2024.

מידע ביבליוגרפי
מחבר ראשי:	Karim, Azrin
מחברים אחרים:	Islam, Farzana
פורמט:	Project report
שפה:	English
יצא לאור:	Brac University 2024
נושאים:	PARP inhibitors Olaparib Talazoparib DNA damage repair DDR signaling pathway Homologous recombination repair Prostate cancer Ovarian cancer Metastatic breast cancer BRCA mutations Cancer > Treatment > Genetic aspects. DNA repair. NAD-ADP-ribosyltransferase > Inhibitors > Therapeutic use. Antineoplastic agents.
גישה מקוונת:	http://hdl.handle.net/10361/24372

http://hdl.handle.net/10361/24372

פריטים דומים